STEM CELLS: Verlust halbiert; Cash verdoppelt - 500 Beiträge pro Seite

[Mattek]

Mahlzeit,

Verlust halbiert und Cash verdoppelt. O.K. in erster Linie sensationelle Zahlen auf Grund des Verkaufs der Modex-Anteile.

Aber gerade für Stemm Cells ist der Cash wahnsinnig wichtig, um das große Ziel, nämlich den Break-Even überhaupt zu erreichen.

Gehe doch stark davon aus, dass die Amis auf diese Zahlen anspringen werden und heute die 3 $ im Handstreich genommen werden.

Dies ist einzig meine persönliche Einschätzung und keine Aufforderung zum Kauf.

Also, nehmt dies und genießt:

(Auszug)
StemCells, Inc. Reports Fourth Quarter and Year End 2001 Results


PALO ALTO, Calif., Mar 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- StemCells,
Inc. (Nasdaq: STEM) announced today financial results for the fourth quarter and
fiscal year ended December 31, 2001.

The Company reported a net loss of $3,524,000 or $0.15 per share, for the fourth
quarter ended December 31, 2001, compared to a net loss of $6,260,000, or $0.30
per share, for the fourth quarter of 2000. For the fiscal year ended December
31, 2001, the Company reported a net loss of $3,446,000 or $0.15 per share
applicable to common shareholders before deemed dividends, as compared to a net
loss of $11,125,000 or $0.57 per share, for the 2000 fiscal year. The net loss
after deemed dividends for fiscal year 2001 is $4,190,000 or $0.19 per share
applicable to common shareholders, as compared to a net loss of $11,606,000 or
$0.58 per share, for the 2000 fiscal year. Total revenue for 2001 was $805,000,
compared with $74,000 in 2000. Revenue for 2001 was from grants and assignment
of rights to technology, while revenue for 2000 was from collaborative
agreements. Cash, and cash equivalents, were $13,697,000 at the end of 2001,
compared with $6,069,000 at the end of 2000.

The decrease in net loss from 2000 to 2001 was attributed primarily to a
realized gain on the sale of StemCells` remaining holdings in Modex
Therapeutics, offset by an increase in operating expenses due to the expansion
of the Company`s research and development activities.

"StemCells continued to make progress in 2001 with its proprietary technologies
for the identification, purification and expansion of adult stem cells derived
from human organ tissue," said Martin McGlynn, the Company`s president and CEO.
"The first of the Company`s proprietary organ-derived stem cells, the human
neural stem cell, has been shown to not only survive transplantation, but to
give rise to the robust production of mature neural cells in small animal
models. In 2001, we established multiple master cell banks, containing highly
purified and well-characterized human neural stem cells for use in our recently
initiated pre-clinical testing program in animal models of central nervous
system disease. We were also happy to report the award of two significant
multi-year grants by the National Institutes of Health for our human liver stem
cell discovery program."

StemCells Inc. is a biotechnology company focused on the discovery, development
and commercialization of stem cell-based therapies to treat diseases of the
central nervous system, liver and pancreas. The company`s stem cell programs
seek to repair or repopulate neural or other tissue that has been damaged or
lost as a result of disease or injury.


Happy Trading,
Mattek

[Mattek]

mmmhhh,

scheine mit meiner Einschätzung nicht ganz alleine da zustehen.

3,20e in FFM

So long,
mattek

[Alex2210]

Was meinst du wie es in den USA heute läuft?
Hast du schon einen vorbörslichen Kurs?

Gruss Alexx

[Mattek]

Tja, ist so eine Sache mit Tipps.

Vom nackten Zahlenmaterial erwarte ich einen Anstieg, der nördlich der 3 $ endet. Aber wen interessieren meine Erwartungen.

Vorbörslich noch nix los.

So long,
mattek